Vikram Narayan, MD, on cystectomy outcomes in nadofaragene-treated patients
December 9th 2024“Overall, the take-home message is that in patients with BCG-unresponsive non–muscle-invasive bladder cancer, you can consider nadofaragene as an option among those that are available for treating these patients,” says Vikram M. Narayan, MD.
Kara Watts, MD, outlines SUO 2024 session on salvage focal ablation
December 7th 2024"I think the highlights are the functional outcomes after a salvage focal ablation are favorable, definitely, compared to salvage radical prostatectomy, but the studies are quite limited in terms of real salvage focal ablation," says Kara L. Watts, MD.
Gal Wald, MD, on the rationale for trial of BCG plus gemcitabine in NMIBC
December 6th 2024"Combination therapies have now become the forefront of our field, and we are trying to do better to avoid BCG-unresponsive disease, as well as progression to either muscle-invasive or metastatic disease," says Gal Wald, MD.
Expert details questionnaire for female partners of patients with prostate cancer
November 27th 2024"Honestly, there really isn't another measure of sexual quality of life for females that addresses the specific concerns of the female partners of patients with prostate cancer," says Stacy Loeb, MD, MSc, PhD (hon).